Intersect ENT, Inc. – NASDAQ:XENT
Intersect ENT stock price today
Intersect ENT stock price monthly change
Intersect ENT stock price quarterly change
Intersect ENT stock price yearly change
Intersect ENT key metrics
Market Cap | N/A |
Enterprise value | 1.08B |
P/E | -10.53 |
EV/Sales | 10.42 |
EV/EBITDA | -6.84 |
Price/Sales | 9.16 |
Price/Book | -10.13 |
PEG ratio | 0.09 |
EPS | -5.09 |
Revenue | 103.99M |
EBITDA | -158.54M |
Income | -170.46M |
Revenue Q/Q | -11.31% |
Revenue Y/Y | 22.26% |
Profit margin | -161.94% |
Oper. margin | -143.41% |
Gross margin | 71.88% |
EBIT margin | -143.41% |
EBITDA margin | -152.46% |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeIntersect ENT stock price history
Intersect ENT stock forecast
Intersect ENT financial statements
| Jun 2021 | 27.34M | -16.60M | -60.7% |
|---|---|---|---|
| Sep 2021 | 24.4M | -31.84M | -130.53% |
| Dec 2021 | 30.67M | -91.15M | -297.2% |
| Mar 2022 | 21.57M | -30.85M | -143.03% |
| 2021-08-06 | -0.42 | -0.49 |
|---|---|---|
| 2021-11-02 | -0.42 | -0.48 |
| Jun 2021 | 200860000 | 159.22M | 79.27% |
|---|---|---|---|
| Sep 2021 | 227966000 | 211.75M | 92.89% |
| Dec 2021 | 146867000 | 215.93M | 147.03% |
| Mar 2022 | 127393000 | 221.42M | 173.81% |
| Jun 2021 | -13.61M | 19.14M | 1.39M |
|---|---|---|---|
| Sep 2021 | -13.36M | 13.82M | 37.05M |
| Dec 2021 | -15.71M | -1.42M | -2.98M |
| Mar 2022 | -26.86M | -2.70M | 15.82M |
Intersect ENT alternative data
| Aug 2023 | 433 |
|---|---|
| Sep 2023 | 433 |
| Oct 2023 | 433 |
| Nov 2023 | 433 |
| Dec 2023 | 433 |
| Jan 2024 | 433 |
| Feb 2024 | 433 |
| Mar 2024 | 433 |
| Apr 2024 | 433 |
| May 2024 | 433 |
| Jun 2024 | 433 |
| Jul 2024 | 433 |
Intersect ENT other data
| Period | Buy | Sel |
|---|---|---|
| Apr 2019 | 0 | 84951 |
| May 2019 | 0 | 23850 |
| Jun 2019 | 0 | 350 |
| Nov 2019 | 0 | 25584 |
| Mar 2020 | 34035 | 0 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Option | MOLL FREDERIC H director | Common Stock | 12,500 | N/A | N/A | ||
Option | MOLL FREDERIC H director | Stock Option (right to buy) | 12,500 | N/A | N/A | ||
Purchase | MEIER RICHARD A officer: EVP & Ch.. | Common Stock | 5,000 | N/A | N/A | ||
Purchase | WEST THOMAS A. director, officer.. | Common Stock | 19,035 | N/A | N/A | ||
Purchase | MEIER RICHARD A officer: EVP & Ch.. | Common Stock | 10,000 | N/A | N/A | ||
Option | BINNEY ROBERT H JR officer: Chief Commercial Officer | Stock Option (right to buy) | 21,937 | $13.32 | $292,201 | ||
Option | BINNEY ROBERT H JR officer: Chief Commercial Officer | Common Stock | 21,937 | N/A | N/A | ||
Sale | BINNEY ROBERT H JR officer: Chief Commercial Officer | Common Stock | 25,584 | N/A | N/A | ||
Option | BINNEY ROBERT H JR officer: Chief Commercial Officer | Stock Option (right to buy) | 21,937 | N/A | N/A | ||
Option | STIMSON SUSAN P officer: Chief Strategy Officer | Stock Option (right to buy) | 350 | N/A | N/A |
| Patent |
|---|
Application Filling date: 27 Aug 2021 Issue date: 24 Feb 2022 |
Application Filling date: 17 Aug 2021 Issue date: 9 Dec 2021 |
Grant Filling date: 25 Jan 2017 Issue date: 21 Sep 2021 |
Grant Filling date: 20 Oct 2020 Issue date: 7 Sep 2021 |
Application Filling date: 9 Feb 2021 Issue date: 24 Jun 2021 |
Application Filling date: 27 Aug 2020 Issue date: 4 Mar 2021 |
Application Filling date: 20 Oct 2020 Issue date: 4 Feb 2021 |
Application Filling date: 28 Aug 2020 Issue date: 17 Dec 2020 |
Grant Utility: Drug-coated balloon Filling date: 13 Feb 2020 Issue date: 27 Oct 2020 |
Application Filling date: 18 May 2020 Issue date: 3 Sep 2020 |
| Quarter | Transcript |
|---|---|
| Q1 2021 10 May 2021 | Q1 2021 Earnings Call Transcript |
| Q4 2020 9 Mar 2021 | Q4 2020 Earnings Call Transcript |
| Q2 2020 9 Aug 2020 | Q2 2020 Earnings Call Transcript |
| Q1 2020 12 May 2020 | Q1 2020 Earnings Call Transcript |
Tuesday, 10 May 2022 | ||
| Intersect ENT (XENT) Q1 Earnings & Revenues Miss Estimates | Zacks Investment Research | |
Thursday, 2 December 2021 | ||
| Why Is Intersect ENT (XENT) Down 0.6% Since Last Earnings Report? | Zacks Investment Research | |
Thursday, 18 November 2021 | ||
| Intersect ENT's (XENT) Sell-Off on Track Amid COVID Woes | Zacks Investment Research | |
Thursday, 30 September 2021 | ||
| MedTech Thrives on M&A Frenzy: 3 Stocks to Focus on | Zacks Investment Research | |
Monday, 13 September 2021 | ||
| SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Intersect ENT, Inc. - XENT | PRNewsWire |
-
What's the price of Intersect ENT stock today?
One share of Intersect ENT stock can currently be purchased for approximately $28.24.
-
When is Intersect ENT's next earnings date?
Unfortunately, Intersect ENT's (XENT) next earnings date is currently unknown.
-
Does Intersect ENT pay dividends?
No, Intersect ENT does not pay dividends.
-
What is Intersect ENT's stock symbol?
Intersect ENT, Inc. is traded on the NASDAQ under the ticker symbol "XENT".
-
What is Intersect ENT's primary industry?
Company operates in the Healthcare sector and Medical - Devices industry.
-
How do i buy shares of Intersect ENT?
Shares of Intersect ENT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Intersect ENT's key executives?
Intersect ENT's management team includes the following people:
- Mr. Thomas A. West Pres, Chief Executive Officer & Director(age: 61, pay: $908,970)
- Mr. Richard A. Meier Executive Vice President & Chief Financial Officer(age: 65, pay: $621,760)
- Mr. Patrick A. Broderick Executive Vice President, Gen. Counsel & Corporation Sec.(age: 66, pay: $138,460)
-
How many employees does Intersect ENT have?
As Jul 2024, Intersect ENT employs 433 workers.
-
When Intersect ENT went public?
Intersect ENT, Inc. is publicly traded company for more then 11 years since IPO on 24 Jul 2014.
-
What is Intersect ENT's official website?
The official website for Intersect ENT is intersectent.com.
-
Where are Intersect ENT's headquarters?
Intersect ENT is headquartered at 1555 Adams Dr, Menlo Park, CALIFORNIA.
-
How can i contact Intersect ENT?
Intersect ENT's mailing address is 1555 Adams Dr, Menlo Park, CALIFORNIA and company can be reached via phone at +1 650 641 2100.
Intersect ENT company profile:
Intersect ENT, Inc.
intersectent.comNASDAQ
433
Medical - Devices
Healthcare
Intersect ENT, Inc. operates as an ear, nose, and throat (ENT) medical technology company in the United States. The company offers PROPEL, a steroid releasing implant to open the surgically enlarged sinus; PROPEL Mini, a releasing implant to treat patients undergoing frontal sinus surgery; and PROPEL Contour, a steroid releasing implant for the treatment of frontal and maxillary sinus ostia, or openings, of the dependent sinuses. It also provides SINUVA, a steroid releasing implant for the treatment of patients in the physician office setting; VENSURE Navigable and Stand-alone balloon, a sterile and single-use device, used to access and treat frontal, sphenoid sinus, and maxillary ostia in adults using a trans-nasal approach; and CUBE Navigation System, a virtual guidance platform for high precision ENT and ENT related skull-base surgeries. The company was formerly known as Sinexus, Inc. and changed its name to Intersect ENT, Inc. in November 2009. Intersect ENT, Inc. was incorporated in 2003 and is headquartered in Menlo Park, California.
Menlo Park, CALIFORNIA 94025
CIK: 0001271214
ISIN: US46071F1030
CUSIP: 46071F103
